These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 2236509

  • 1. Studies with bifunctional bioreductive drugs. I. In vitro oncogenic transforming potential.
    Hei TK, He ZY, Piao CQ, Hall EJ.
    Radiat Res; 1990 Oct; 124(1 Suppl):S44-9. PubMed ID: 2236509
    [Abstract] [Full Text] [Related]

  • 2. Mechanism of oncogenicity for bioreductive drugs.
    Hei TK, Piao CQ, He ZY, Hall EJ.
    Int J Radiat Oncol Biol Phys; 1992 Oct; 22(4):747-50. PubMed ID: 1544847
    [Abstract] [Full Text] [Related]

  • 3. Oncogenic transforming potential of nitroimidazole radiosensitizers.
    Hall EJ, Hei TK.
    Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1231-4. PubMed ID: 2523882
    [Abstract] [Full Text] [Related]

  • 4. Studies with bifunctional bioreductive drugs. II. Cytotoxicity assayed with A-549 lung carcinoma cells of human origin.
    Roizin-Towle L, Pirro JP, Hall EJ.
    Radiat Res; 1990 Oct; 124(1 Suppl):S50-5. PubMed ID: 2236511
    [Abstract] [Full Text] [Related]

  • 5. Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.
    Cole S, Stratford IJ, Adams GE, Fielden EM, Jenkins TC.
    Radiat Res; 1990 Oct; 124(1 Suppl):S38-43. PubMed ID: 2236508
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Oncogenic potential of bifunctional bioreductive drugs.
    Hei TK, Liu SX, Hall EJ.
    Br J Cancer Suppl; 1996 Jul; 27():S57-60. PubMed ID: 8763847
    [Abstract] [Full Text] [Related]

  • 8. Potentiation of alkylating chemotherapy by dual function nitrofurans in multi-cell spheroids and solid tumors.
    Siemann DW, Sutherland RM.
    Radiother Oncol; 1992 Aug; 24(4):239-45. PubMed ID: 1410579
    [Abstract] [Full Text] [Related]

  • 9. Comparative DNA damage induced by nitroimidazole-aziridine drugs: 1. Effects of methyl substitution on drug action.
    Dale LD, Tocher JH, Edwards DI.
    Anticancer Drug Des; 1988 Dec; 3(3):169-75. PubMed ID: 3207464
    [Abstract] [Full Text] [Related]

  • 10. Dual-function radiation sensitizers and bioreductive drugs: factors affecting cellular uptake and sensitizing efficiency in analogues of RSU 1069.
    Walling J, Stratford IJ, Adams GE, Stephens MA.
    Int J Radiat Biol Relat Stud Phys Chem Med; 1988 Apr; 53(4):641-9. PubMed ID: 3258298
    [Abstract] [Full Text] [Related]

  • 11. Oncogenic transformation systems involving mammalian cells in vitro to determine the relative risks of different treatment modalities.
    Hall EJ.
    Strahlentherapie; 1984 Dec; 160(12):725-31. PubMed ID: 6515665
    [Abstract] [Full Text] [Related]

  • 12. Analogues of RSU-1069: radiosensitization and toxicity in vitro and in vivo.
    Ahmed I, Jenkins TC, Walling JM, Stratford IJ, Sheldon PW, Adams GE, Fielden EM.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1079-81. PubMed ID: 3755711
    [Abstract] [Full Text] [Related]

  • 13. RSU 1069, a 2-nitroimidazole containing an alkylating group: high efficiency as a radio- and chemosensitizer in vitro and in vivo.
    Adams GE, Ahmed I, Sheldon PW, Stratford IJ.
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1653-6. PubMed ID: 6548211
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
    Binger M, Workman P.
    Cancer Chemother Pharmacol; 1991 Sep; 29(1):37-47. PubMed ID: 1742848
    [Abstract] [Full Text] [Related]

  • 15. Studies on the mechanisms of the radiosensitizing and cytotoxic properties of RSU-1069 and its analogues.
    Walling JM, Stratford IJ, Adams GE, Silver AR, Ahmed I, Jenkins TC, Fielden EM.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1083-6. PubMed ID: 3755712
    [Abstract] [Full Text] [Related]

  • 16. The experimental development of bioreductive drugs and their role in cancer therapy.
    Workman P, Stratford IJ.
    Cancer Metastasis Rev; 1993 Jun; 12(2):73-82. PubMed ID: 8375022
    [Abstract] [Full Text] [Related]

  • 17. Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo.
    Adams GE, Ahmed I, Sheldon PW, Stratford IJ.
    Br J Cancer; 1984 May; 49(5):571-7. PubMed ID: 6547051
    [Abstract] [Full Text] [Related]

  • 18. Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.
    Cole S, Stratford IJ, Bowler J, Nolan J, Wright EG, Lorimore SA, Adams GE.
    Int J Radiat Oncol Biol Phys; 1991 Jul; 21(2):387-95. PubMed ID: 2061115
    [Abstract] [Full Text] [Related]

  • 19. Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents.
    Sebolt-Leopold JS, Vincent PW, Beningo KA, Elliott WL, Leopold WR, Heffner TG, Wiley JN, Stier MA, Suto MJ.
    Int J Radiat Oncol Biol Phys; 1992 Jul; 22(3):549-51. PubMed ID: 1531213
    [Abstract] [Full Text] [Related]

  • 20. Fused pyrazine mono-n-oxides as bioreductive drugs. II Cytotoxicity in human cells and oncogenicity in a rodent transformation assay.
    Langmuir VK, Laderoute KR, Mendonca HL, Sutherland RM, Hei TK, Liu SX, Hall EJ, Naylor MA, Adams GE.
    Int J Radiat Oncol Biol Phys; 1996 Jan 01; 34(1):79-84. PubMed ID: 12118568
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.